Table 1.
Entry characteristics of OPTIMA cohort by treatment strategy*
| Characteristic | Strategy 1 (N=368) | Strategy 2 (N=339) | ||
|---|---|---|---|---|
| Standard N (%) | Intensive N (%) | Interruption N (%) | Continuation N (%) | |
| No. randomized | 192 | 176 | 164 | 175 |
| Age (years) - mean (SD) | 48 (9) | 48 (8) | 49 (8) | 49 (8) |
| Male | 189 (98) | 172 (98) | 160 (98) | 172 (98) |
| White | 90 (47) | 90 (51) | 73 (45) | 87 (50) |
| Black | 80 (42) | 64 (36) | 67 (41) | 71 (41) |
| AIDS or prior AIDS at entry | 107 (56) | 109 (62) | 95 (58) | 105 (60) |
| Hepatitis B virus infection | 26 (14) | 13 (7) | 23 (14) | 14 (8) |
| Hepatitis C virus infection | 46 (24) | 34 (19) | 39 (24) | 38 (22) |
| HIV RNA copies/ml -mean log10 (SD) | 4.7 (0.6) | 4.7 (0.8) | 4.7 (0.7) | 4.8 (0.7) |
| CD4 cells/ul – mean (SD) | 129 (107) | 125 (106) | 129 (106) | 131 (109) |
| Veterans Aging Cohort Study Index | 34.2 (15.6) | 35.0 (15.4) | 34.6 (15.6) | 35.2 (15.3) |
*
29 United Kingdom patients opted to be randomized to the standard or intensive antiretroviral treatment strategy only
SD = standard deviation